Terms: = Prostate cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566
165 results:
1. A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant prostate cancer.
Ye PC; Leu WJ; Yeh TY; Hsu YT; Lin YC; Wei ZY; Chen YC; Chiang YC; Hsu JL; Chan SH; Hsu LC; Chern JW; Yu CW; Guh JH
Prostate; 2024 May; 84(6):605-619. PubMed ID: 38375594
[TBL] [Abstract] [Full Text] [Related]
2. Functional variants of the chitinase 3-like 1 gene are associated with clinicopathologic outcomes and progression of prostate cancer.
Wen YC; Lin CY; Ho KH; Lin YW; Hsiao CH; Wang SS; Chang LC; Yang SF; Chien MH
J Cell Mol Med; 2023 Dec; 27(24):4202-4214. PubMed ID: 37902124
[TBL] [Abstract] [Full Text] [Related]
3. The predictive value of machine learning and nomograms for lymph node metastasis of prostate cancer: a systematic review and meta-analysis.
Wang H; Xia Z; Xu Y; Sun J; Wu J
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):602-613. PubMed ID: 37488275
[TBL] [Abstract] [Full Text] [Related]
4. Experience with the US health care system for Black and White patients with advanced prostate cancer.
Rencsok EM; Stopsack KH; Slopen N; Odedina FT; Ragin C; Nowak J; McSwain L; Manarite J; Heath E; George DJ; Kantoff PW; Vinson J; Villanti P; Haneuse S; Mucci LA;
Cancer; 2023 Aug; 129(16):2532-2541. PubMed ID: 37246339
[TBL] [Abstract] [Full Text] [Related]
5. Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk prostate cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Sartor O; Karrison TG; Sandler HM; Gomella LG; Amin MB; Purdy J; Michalski JM; Garzotto MG; Pervez N; Balogh AG; Rodrigues GB; Souhami L; Reaume MN; Williams SG; Hannan R; Jones CU; Horwitz EM; Rodgers JP; Feng FY; Rosenthal SA
Eur Urol; 2023 Aug; 84(2):156-163. PubMed ID: 37179241
[TBL] [Abstract] [Full Text] [Related]
6. [
Graef J; Bluemel S; Brenner W; Amthauer H; Truckenmueller P; Kaul D; Vajkoczy P; Onken JS; Furth C
J Nucl Med; 2023 Jun; 64(6):892-895. PubMed ID: 37116918
[TBL] [Abstract] [Full Text] [Related]
7. Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer.
Roy S; Wallis CJD; Morgan SC; Kishan AU; Le ATT; Malone J; Sun Y; Spratt DE; Saad F; Malone S
Prostate; 2023 Jul; 83(10):912-921. PubMed ID: 37071764
[TBL] [Abstract] [Full Text] [Related]
8. A hybrid radioactive and fluorescence approach is more than the sum of its parts; outcome of a phase II randomized sentinel node trial in prostate cancer patients.
Wit EMK; KleinJan GH; Berrens AC; van Vliet R; van Leeuwen PJ; Buckle T; Donswijk ML; Bekers EM; van Leeuwen FWB; van der Poel HG
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2861-2871. PubMed ID: 37036490
[TBL] [Abstract] [Full Text] [Related]
9. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study.
Jin P; Shen J; Yang L; Zhang J; Shen A; Bao J; Wang X
BMC Med Imaging; 2023 Mar; 23(1):47. PubMed ID: 36991347
[TBL] [Abstract] [Full Text] [Related]
10. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract] [Full Text] [Related]
11. Endocrine Disrupting Chemicals Influence Hub Genes Associated with Aggressive prostate cancer.
Alwadi D; Felty Q; Yoo C; Roy D; Deoraj A
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834602
[TBL] [Abstract] [Full Text] [Related]
12. Association of prostate-Specific Antigen Screening Rates With Subsequent Metastatic prostate cancer Incidence at US Veterans Health Administration Facilities.
Bryant AK; Lee KM; Alba PR; Murphy JD; Martinez ME; Natarajan L; Green MD; Dess RT; Anglin-Foote TR; Robison B; DuVall SL; Lynch JA; Rose BS
JAMA Oncol; 2022 Dec; 8(12):1747-1755. PubMed ID: 36279204
[TBL] [Abstract] [Full Text] [Related]
13. Identification of the Key Genes Involved in the Tumorigenesis and Prognosis of prostate cancer.
Wang W; Wu Q; Mohyeddin A; Liu Y; Liu Z; Ge J; Zhang B; Shi G; Wang W; Wu D; Wang F
Comput Math Methods Med; 2022; 2022():5500416. PubMed ID: 36245843
[TBL] [Abstract] [Full Text] [Related]
14. Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer.
Hakozaki Y; Yamada Y; Kawai T; Nakamura M; Takeshima Y; Iwaki T; Teshima T; Kinoshita Y; Fujii Y; Akiyama Y; Sato Y; Yamada D; Suzuki M; Kashiwagi-Hakozaki M; Ushiku T; Kume H
Sci Rep; 2022 Sep; 12(1):16202. PubMed ID: 36171391
[TBL] [Abstract] [Full Text] [Related]
15. A supervised machine learning approach identifies gene-regulating factor-mediated competing endogenous RNA networks in hormone-dependent cancers.
Jayarathna DK; Rentería ME; Batra J; Gandhi NS
J Cell Biochem; 2022 Aug; 123(8):1394-1408. PubMed ID: 35757968
[TBL] [Abstract] [Full Text] [Related]
16. Socioeconomic differences in prostate cancer treatment: A systematic review and meta-analysis.
Gallagher BDT; Coughlin EC; Nair-Shalliker V; McCaffery K; Smith DP
Cancer Epidemiol; 2022 Aug; 79():102164. PubMed ID: 35526516
[TBL] [Abstract] [Full Text] [Related]
17. Environmental Phenol and Paraben Exposure Risks and Their Potential Influence on the Gene Expression Involved in the Prognosis of prostate cancer.
Alwadi D; Felty Q; Roy D; Yoo C; Deoraj A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409038
[TBL] [Abstract] [Full Text] [Related]
18. Robotic-assisted Versus Laparoscopic Radical prostatectomy: 12-month Outcomes of the Multicentre Randomised Controlled LAP-01 Trial.
Stolzenburg JU; Holze S; Arthanareeswaran VK; Neuhaus P; Do HM; Haney CM; Dietel A; Truss MC; Stützel KD; Teber D; Hohenfellner M; Rabenalt R; Albers P; Mende M
Eur Urol Focus; 2022 Nov; 8(6):1583-1590. PubMed ID: 35216946
[TBL] [Abstract] [Full Text] [Related]
19. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
[TBL] [Abstract] [Full Text] [Related]
20. Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in prostate cancer.
Ning R; Pei Y; Li P; Hu W; Deng Y; Hong Z; Sun Y; Zhang Q; Guo X
Front Public Health; 2021; 9():777160. PubMed ID: 34950631
[No Abstract] [Full Text] [Related]
[Next]
